New lung cancer drug enters final testing phase
NCT ID NCT07383116
Summary
This study aims to see if a new drug called HB0025 works better than an existing drug called tislelizumab when each is combined with standard chemotherapy. It is for adults with advanced non-squamous non-small cell lung cancer that cannot be surgically removed. About 500 participants will be randomly assigned to receive one of the two drug combinations to compare how long the cancer is kept from growing and the safety of each approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The East Hospital Affiliated to Tongji University
Shanghai, Shanghai 200120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.